Boston Scientific has reported a loss of 15 cents per share in the third quarter of 2015, for a total loss of $198 million. However, the company had a 9 percent increase in operational revenue on a constant currency basis.

Endologix and TriVascular Technologies announced on Oct. 26 that they had signed a definitive merger agreement in a stock and cash deal. The transaction is valued at approximately $211 million based on the closing prices on Oct. 23 of $9.10 per TriVascular share and $13.81 per Endologix share, according to a news release.

Edwards Lifesciences appointed longtime healthcare executive Martha H. Marsh to its board of directors on Oct. 23, according to a company news release.

Since taking over as Medtronic’s CEO, Omar Ishrak has focused on three goals: improving innovation, expanding into emerging markets and becoming a leader in value-based health care, according to a Barron’s article. A Jefferies analyst called Medtronic’s acquisition of Covidien earlier this year a “bold move” and said “Ishrak changed the ethos of the company.”

Boston Scientific announced on Oct. 8 that it had provided additional financing for MValve Technologies, a company that is developing a percutaneous mitral valve replacement system. Boston Scientific said it has an exclusive option to acquire MValve Technologies, a privately held corporation founded in 2011 with operations in San Diego and Herezeliya, Israel.

St. Jude Medical completed its acquisition of Thoratec on Oct. 8, expanding its heart failure business and adding products such as the HeartMate II left ventricular assist device.

Express Scripts announced it would include the two recently FDA-approved proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on its national preferred formulary, which covers approximately 25 million people in the U.S.

On Oct. 29 in Oakland, members of the California Technology Assessment Forum (CTAF) are expected to discuss and debate a report on the cost effectiveness of two recently FDA-approved heart failure treatments.